<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> has a crucial role in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), being responsible of the ineffective hematopoiesis characteristic of the disease </plain></SENT>
<SENT sid="1" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> rate is elevated in "early phase" <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, whereas it diminishes during disease progression to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, consensually to the acquisition of independent growth features </plain></SENT>
<SENT sid="2" pm="."><plain>Survivin is a member of the inhibitor of the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (IAP) family, with the bifunctional role of suppressing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> while facilitating cell cycle progression </plain></SENT>
<SENT sid="3" pm="."><plain>We investigated Survivin <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels by real-time quantitative reverse transcriptase PCR analysis and Survivin protein expression by immunohistochemistry in 49 bone marrow (BM) aspirates and in 17 BM biopsies (BMB) from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Survivin <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels were higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> than in control group (1.68 +/- 1.46 vs 0.25 +/- 0.22; p &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with low or INT1 International Scoring System for Evaluating Prognosis (IPSS) displayed higher levels of Survivin <z:chebi fb="2" ids="33699">mRNA</z:chebi> in comparison to INT2 or high IPSS (1.91 +/- 1.51 vs 0.88 +/- 0.95; p = 0.0058) </plain></SENT>
<SENT sid="6" pm="."><plain>Survivin protein immunoreactivity was evaluated as Survivin index S ((i)) and calculated according to the formula: S ((i)) = % of Survivin positive cells x BMB cellularity / 100 </plain></SENT>
<SENT sid="7" pm="."><plain>Survivin index was higher in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> group than in <z:mpath ids='MPATH_458'>normal</z:mpath> BM (p = 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, in eight cases in which BM aspirates and trephine biopsy were available, we found a significant association between the level of Survivin <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression (p = 0.011) </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, this study demonstrates increased levels of Survivin in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> compared to <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, higher levels of transcripts are related to "low-risk" <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Our results suggest an active role of Survivin in <z:mpath ids='MPATH_458'>normal</z:mpath> and in myelodysplastic hematopoiesis </plain></SENT>
</text></document>